OCS
Price
$13.15
Change
-$0.48 (-3.52%)
Updated
Jul 13 closing price
Capitalization
798.33M
24 days until earnings call
Intraday BUY SELL Signals
PRAX
Price
$314.56
Change
-$10.43 (-3.21%)
Updated
Jul 13 closing price
Capitalization
8.77B
28 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

OCS vs PRAX

OCS vs PRAX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
OCS vs. PRAX commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OCS is a Hold and PRAX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 14, 2026
Stock price -- (OCS: $13.63 vs. PRAX: $314.56)
Brand notoriety: OCS and PRAX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OCS: 10% vs. PRAX: 28%
Market capitalization -- OCS: $798.33M vs. PRAX: $8.77B
OCS [@Biotechnology] is valued at $798.33M. PRAX’s [@Biotechnology] market capitalization is $8.77B. The market cap for tickers in the [@Biotechnology] industry ranges from $121.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OCS’s FA Score shows that 0 FA rating(s) are green whilePRAX’s FA Score has 0 green FA rating(s).

  • OCS’s FA Score: 0 green, 5 red.
  • PRAX’s FA Score: 0 green, 5 red.
According to our system of comparison, PRAX is a better buy in the long-term than OCS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OCS’s TA Score shows that 4 TA indicator(s) are bullish while PRAX’s TA Score has 4 bullish TA indicator(s).

  • OCS’s TA Score: 4 bullish, 4 bearish.
  • PRAX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, OCS is a better buy in the short-term than PRAX.

Price Growth

OCS (@Biotechnology) experienced а -3.47% price change this week, while PRAX (@Biotechnology) price change was +0.34% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.13%. For the same industry, the average monthly price growth was +7.30%, and the average quarterly price growth was +1806.57%.

Reported Earning Dates

OCS is expected to report earnings on Aug 06, 2026.

PRAX is expected to report earnings on Aug 10, 2026.

Industries' Descriptions

@Biotechnology (-3.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRAX($8.77B) has a higher market cap than OCS($798M). PRAX YTD gains are higher at: 6.725 vs. OCS (-34.151). OCS has higher annual earnings (EBITDA): -93.55M vs. PRAX (-357.2M). PRAX has more cash in the bank: 787M vs. OCS (222M). PRAX has less debt than OCS: PRAX (1.44M) vs OCS (2.25M). OCS (0) and PRAX (0) have equivalent revenues.
OCSPRAXOCS / PRAX
Capitalization798M8.77B9%
EBITDA-93.55M-357.2M26%
Gain YTD-34.1516.725-508%
P/E Ratio63.08N/A-
Revenue00-
Total Cash222M787M28%
Total Debt2.25M1.44M157%
TECHNICAL ANALYSIS
Technical Analysis
OCSPRAX
RSI
ODDS (%)
Bullish Trend 4 days ago
75%
Bearish Trend 4 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
36%
Bearish Trend 4 days ago
82%
Momentum
ODDS (%)
Bullish Trend 4 days ago
61%
Bearish Trend 4 days ago
81%
MACD
ODDS (%)
Bullish Trend 4 days ago
62%
Bullish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
52%
Bullish Trend 4 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
59%
Bullish Trend 4 days ago
89%
Advances
ODDS (%)
Bullish Trend 18 days ago
73%
Bullish Trend 5 days ago
85%
Declines
ODDS (%)
Bearish Trend 26 days ago
62%
Bearish Trend 12 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
40%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
52%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
OCS
Daily Signal:
Gain/Loss:
PRAX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LINE43.850.73
+1.69%
Lineage Inc.
SRCE81.740.30
+0.37%
1st Source Corp
USNA22.030.05
+0.23%
USANA Health Sciences
KVACU12.19N/A
N/A
Keen Vision Acquisition Corp
FEAM1.29-0.02
-1.53%
5E Advanced Materials Inc.

OCS and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCS has been loosely correlated with NXTC. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if OCS jumps, then NXTC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCS
1D Price
Change %
OCS100%
-3.52%
NXTC - OCS
37%
Loosely correlated
+10.66%
FTH - OCS
32%
Poorly correlated
-7.74%
NUVL - OCS
31%
Poorly correlated
+0.03%
GRI - OCS
30%
Poorly correlated
-6.90%
PRAX - OCS
29%
Poorly correlated
-3.21%
More

PRAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRAX has been loosely correlated with BEAM. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if PRAX jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRAX
1D Price
Change %
PRAX100%
-3.21%
BEAM - PRAX
40%
Loosely correlated
-5.14%
ANRO - PRAX
38%
Loosely correlated
+5.85%
BHVN - PRAX
37%
Loosely correlated
-2.44%
RAPP - PRAX
35%
Loosely correlated
-2.78%
TOVX - PRAX
35%
Loosely correlated
-3.27%
More